Loading...
Docoh

Adicet Bio (ACET)

Participants
Jody Burfening Investor Relations, LHA
Albert L. Eilender Chairman
William C. Kennally, III President and CEO
Douglas Roth SVP and CFO
Walter Kaczmarek, III COO
Dewey Steadman Canaccord Genuity
Matthew Hewitt Craig-Hallum Capital Group
Steve Schwartz First Analysis Securities
Greg Eisen Singular Research
Kevin McKenna Main Line Capital
Unidentified Analyst Private Investor
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Good morning and welcome to the Aceto First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Jody Burfening. ahead. go Please

Jody Burfening

Kennally, Financial issued Aceto's Chief and Officer. Corporation's after Anita With everyone welcome earnings release are its with first is Operating Q&A the the and today and Kaczmarek, participate Thank yesterday to quarter good fiscal Aceto quarter Bill call today this in first providing Walt market call. session. and XXXX Chief to CEO; and Doug you, on morning President Officer also earnings Roth, me us The closed. company press conference

the you a Investor For have company's those of who of section is not website the yet in seen www.aceto.com. release, available at the copy Relations

standards actual by XXXX as believe, Before identified like income today's These and remind starting such Chairman will trends that that adjusted by to call, and amortization that impact per Litigation certain measures words cost in analyze Al. going earnings plans, operations results materially a to result anticipate, discounts and company's a update morning you to in accounting to similar net could the company's be today’s as factors Aceto's on to are that introductory the call, today's Eilender, Also The differ cost, share To I'd period few make certain investors prior as start numerous Reform Commission. and Act company's operating Private expressions can business. of Aceto's debt fundamental Aceto's to statements the Good management Al involve based anticipated intangibles, non-GAAP forth Securities performance call filings results the Exchange as be set remarks. current of contain is the seeks, from or by referring Securities with of forward-looking and period projects, and of the excluding of related adjusted extinguishment, net issuance of non-GAAP defined compare expect, XXXX-XX. the allow call defined results on measures. income These uncertainties. financial the and of forward-looking measures implied debt statements transactions risks these debt and are will those amortization

Albert L. Eilender

morning Thank morning. joining today a everyone bridge for us to Good the the thank this act Jody. is My new. and you from purpose old to you as

upon last come As focus to scale and of external strategic importance offerings, our drug the we of have company, been assets events years the the to the unchanged. one Board's commercial our buffeted embarked within drug reputable the company's have products, business to competitive about a were generic into starting industry on If Lucid generic important took partner and through forces future generic channels In have more in Citron direction, Rising. acquisition remains the dosage with with focused a significant starting The distribution The specifically its step two pricing on scale. thinking external these increase to number we XXXX manufacturer and of unprecedented. our strategic to unit of an a and finished intense increase pipeline pressures consolidation pharmaceutical transition drugs. of coupled historically the

company's a from perspective eroded Board the and firms business. came in product. value generic and discussions the He role managing in Citron year conclusion in and to the many Board leading seen to would about having course decision understands Kennelly order experience strategy the shuffling rationalizing at tumultuous on an the past lineups moving to was company continue their the forward its of we've challenges to The industry the their benefit acquire served this approving that company's Over craft to business Having the generic of shareholder substantially pharma executive operations, company many and model. fresh Aceto's the companies Board bring has played since Lucid Bill efforts. September XXXX level has active helped involved

CEO brief experience who's Bill a would quarter provide now the will call like a role drive and we Importantly achievements the about to over turn I of the that to the of long-term first observations Aceto believe With to dynamic his Bill. results. and to Bill being brings some leadership share style wealth ultimately industry going company. initial growth of and for a said that overview

William C. Kennally

conference and I'm excited everyone. morning And Al here to for have to good really call. first I you thank say Hey, you my be before

also Doug share before you observations to company I'll from with results. the of helpful you to might I'd performance the the with will be And over Organization. to who and about to you my to recap call of are Aceto relevant like, quarter so my how transition analysis path my of a more there to bit provide like Health in-depth run experiences the all I'd initial a turning first a it and give Human background and

that model have the I the of there to made You Pharmacia assignments the the a the of in with the guy. we blockbuster including revenue took generic end in where carrying Upjohn for drugs join part products to of know When a front XX Senior of bag late I amount sales had first XX the this rose as to I six my Pfizer was merged called trade of of corporation that ins Pharmacia an company and business this years a captured to hidden of and lost by otherwise numerous We launch opportunity launched sales commercial acquisition, the It started in generics. Management interest variety next earnings. the years discovered competition. Pfizer through the with and acquired over products tremendous next where a moved business. When out management against and and and on number the outs learned XXs branded District I authorized designed positions Manager Upjohn and label I'm of series generics generic then I a been gem earnings competing corporate a the Greenstone, business the line revenue captured would years.

Our Greenstone opportunity North revenue. Pfizer's a five with gave where was P&L with in just America for under lead success separate the I businesses of to established billion running annual combined and business products responsible manage in X me

and meaningful franchises ones small especially to company successful human chance leadership business objectives. running health me a pharma What had my workings Hospira provided new and of the we During an forward bring jumped business Pfizer well in towards eventually ground has and privilege businesses experience and larger built injectable strategy the on led of I role to scratch in strategic left my an that my acquisition. as serve providing brought help in people arena. generic at Aceto look the as expertise always as opportunity to top independent products shape background. Board pharma in strong Aceto to I creating to time on opportunity to I the up. When from to that the building I tier generic been for into Aceto's passion. role inner return Aceto the I and exposed a which its primarily with Board presented to knowledge the leading commercial the from the industry CEO And a When Serving my moving is the my on director

every for the I sometimes a leader a culture urgency day their generics and own not as every requires not complex culture an means risk. to end fast, becomes point and required owned order where to advocating And environment goal taking master. organization. employee of turning is towards mistakes and the drives part and engagement creating in your organization the that where What and me is an to ownership hour. making really a yet firsthand have generally results. A of sense where be empowering to to to that norm you dynamic part in everyone I creating it am you acceptable encourage that's in business. a industry take tell can it's I've along an is learned colleagues how dealings ownership they're culture risk needs are of you with vetted. and So to fully you take as had to I industry, engagement and And It's flexible, then appetite if your mentor that was and day long success mistakes making chance drive present boss an day but the risks. that's in successful. accountability the creating I of risky you generic former and know to ever day not it's Well witness decisions different exciting have and in to once need I've as hear focused to every comes it's multiple told ownership risks enough was the It's And

my there. get vibrant the business So here is confident we we'll works that best to a instill for culture operate. but goal process It's I'm a

is due of to the at started by country. impressed our government in folks to with responded that closed their I'm Chinese of past good hazards in example A hood China very the people learning I've the few have jobs. environmental have thousands recent they're weeks I'm Over the crackdown under been to there a on plants the looking quality why our and and organization beautifully

and job the the think how do amazing an that risk if risk us. me is proud they've And around Aceto where mitigated ensuring had contained think potential partners with and stayed speaks material globe. any our to to that correspondences done they reaching businesses the ahead to I've I'm potential of team to we have I the there challenge. also reputation business colleagues from not this successfully. real have this out can Our all We asking of is

partners it's want our continue that and We of be want terrific others to work plans. source to to with part we

our help reach We markets. objectives our all that have partner us developmental in with should extraordinary

meet I when and at colleagues, out, remove work challenges the company effort So Aceto face, the near-term inside the they it's meaning with every obstacles. to understanding look to from make priorities

meet I partners to addition all can will best building that our with We're preferred and customers platform support we we compete of in to markets. supplier. need to a effectively trying the and Aceto's understand how be plan In functional

to generics asset there sustainable on have slide which leverage ways opportunities However, in deck Longer-term path company our to we're to model success. investor in up whiteboard depicted move we and just lot a and the an of our is industry the these finding can steps that like relationships API a not as offers our updated critical expand resources. are put yet as well up partner back chain the value we

across the looking our a We profit I'll human our on job raise performance in and also in but gross pharma Board margins need to do just better segments. to ways be chemical our health not and ingredients for

work to to be successful to and outcomes company's path will the do have We it exciting see how evolves.

Net own, to million of performance the compared million And now year. compare we our reported On with X.X XX.X non-GAAP income which to generally Turning of adjusted final X% quarter We XXXX. was XXX first $X.XX generated a sales $X.XX, line now to was to over million was our in compared were favorably net results I million quarter up to last X.X expectations the XXX.X income increase. year. a and fiscal EPS last million. X.X million net non-GAAP XX.X% compared down to modest basis the

on product Rising launches, since our impact the of favorable and quarter first pricing. select inline pricing more sales in negative market legacy select offset for business dynamics new than of competitive increases XXXX year-over-year fiscal posted third share increase as Our products,

$XX collections system paying while of continue task a for million. in facets two quarter. favorable cash for our and pharmaceutical and segments, the long-term for integrating and Citron of of for receivable new and all our increases go business Rising other we the during revenue gross of down the the team this Rising the to ERP warehouse. showed complete improving preparing And which by Our ingredients the debt assets performance remains quarter kudos to chemicals have steady us acquired generators profit Doug of At implementation

which functional We the operation date on ERP will begin accrual quarter now from fully is conversion begin million in allow projects will robust fiscal to rate implementation end towards run our the four. both line critical of of new XX quarter implementation the realize by the a of value the system decision soft transaction of X to fiscal delay Getting fourth the days annualized the an becoming warehouse a ERP new on fully warehouse the allow system quarter strategic date have start these three, and in XXXX. made point of to beginning of as us to of will integrated live. to synergy of quarter the at closely tied is go concurrently four a sale The

moved and into somewhat And the New end We're to recently to Brook, we and larger result currently ensure fiscal the the diligently Rising Jersey. of uninterrupted we're colleagues short-term customers in and are related we supply some of recovery constraints largely office the by that API integration experiencing the work, Saddle full our year. a supply to anticipate new working challenges

During the that approximately we also now our XX maintain products the [ph] communicated. previously have EconDis and projects completed from XXX factors. going and our XX these in with and to projects expect individual in the several now quarter as are our impact pipeline XXX launched harmonization schedule three fourth discussions which XXX negotiations marketing product represent of some forward. we on had to have on customers better call. is we currently Rising for and clarity quarter approximately quarter The XXX compares launch a difference products year reported of to combination the We SKUs. ClarusONE We

we more made product and XX favorable conditions had back the delays halt the XXX products and commercially due total one me, products, developmental for we decision to them adverse market into will commonly, become projects, made less excuse project put beginning intended the and launch queue launched to of three We to we should three With conditions products project, these attractive. added launching. commercial previously market terminated poor

working FDA enhanced we filed quarter also in significantly with ANDA's bringing addition five XX. with ANDA's Rising last number with expertise a operations, strategic place we've the closely sales fresh developments together development, have last now and our the to We're thoroughly want experience. months occur of with us and level. and more over more team the business Senior quality the bringing analytics. and in take improve our and forecasting I've been to in unforeseen industry, the a of operations leaders of a as forecasts. our from of three on look methodology while generic areas the scrub total to file next to Rising leaders and to generic instituting can functional working development now the sharpen XX effectively changes. And some business total taking of During our that Management our finance these at years do perspectives a sales commercial numbers represent I We team the team operational And the combined

other generic assessment Our low the higher pressures bit in the entrants in indicate conditions and and outlook percent erosion new of the our range weighing fiscal annual price for a current double-digit market XXXX. are competitive now market is

resetting growth mentioned API exercises fiscal our being sales net date on few delays pushed were launch In XXXX be outcome a a per products addition diluted XX% per and product to launch reported beyond in we and guidance. and are earnings bottom We I to and Rising between between earnings share due XX% the now a be $X.XX original up this to to that $X.XX of earlier. and $X.XX. $X.XX expect diluted constraints GAAP of range share The net non-GAAP sales

pipeline. R&D million as numbers anticipate million. have Now that's was to adjusted in are milestone reminder moderately for our the the we year. XXXX versus than And finished million R&D to -- second XX the of just be our first spending dose a expenditures previous based. XX XX quarter range our higher approximately of our fiscal generic the XXXX That And for and regarding are first expected reflect fiscal results half the of half to outlook now

to So call I the I'd over like Doug to turn you. could if

Douglas Roth

a XX.X XX.X% million million morning you Thank in addition quarter everyone. compared for the profit fiscal XXXX. Citron increase of was first under XXX XX% of to million, Net reported first the Gross the products. from part and XXX.X XXXX to of Bill year. million first in segment XXX reflecting of increase in quarter margin was large basis sales for were of just sales million quarter On XX.X prior XX.X% first health human of an an segment the compared quarter XX.X% the an reporting or Of which increase first the Gross from in variance good XXXX. XX.X. contributed were products and of quarter XX fiscal million from million, fiscal in the XX XXX% million sales Citron XXXX the -- XX.X were the December the Lucid of acquired

since during first sales legacy were up final its our realized gains quarter addition, fiscal In of year-over-year quarter. modestly Rising XXXX business nutritional the and the sales

the Lucid to products. to margin -- gross year million other gross quarters pardon acquisition. legacy Lucid was The profit was and again Human price a lower addition legacy margin offset profit the to product and on gross primarily margin and gross on me, XX.X gross last product our the Citron by and certain lower of gross of XX.X% products. with XX.X% and lower run due certain XX.X% consistent Rising rate increased health partially were reflecting products the gross is compared where unfavorable two Citron from the gross sales decline Our the Rising prior profitability erosion margin mix reflecting in subsequent to products profit

ingredient to first under XXXX XXXX Gross to API X in just as to a of first launch of primarily XX% X.X the first due the the sales reduced decrease a mix. from XX.X pharmaceutical domestic customer million large quarter profit of quarter in well XX% segment as sales product versus million Our decreased part lower quarter million, API orders due of API. were of in

XX.X increased largely sales due gross specialty quarter agricultural X% compared a profit favorable in pigment was of XX% year. Gross intermediate. higher performance XX.X margin was segment of specialty to sales to to The reflecting down and chemical last first X.X% XXXX from X.X million chemical million the mix less chemical Our million XX.X% of to products.

compared gross last was to year. Our XX.X% XX.X% margin

$X million million XX.X and associated administrative and attributable recent as increased million and million. in the the Citron CEO the to intangible SG&A Arsynco absolute included Lucid a SG&A in quarter in of development the and with last Research costs achievements services year. were and Citron quarter related gross million assets XX of initiations growth, amortization Our products. $XXX,XXX to the costs profit X milestone uneven to first our R&D period product closed want growth remediation onetime year from departure of basis. X.X Jersey. million and million services million remain company's X.X New the project transition the compared operating the The to of million expenses in $X.X expenses related of dropped to was of associated a last with XX.X facility charge With to Also with our former increase a associated modestly and purchase environmental income X.X on the compared to million outpacing X.X quarter-to-quarter SG&A comparable

Our income or a million was year. compared non-GAAP a or share was share basis XX% income or share per the net for net income first net million to of to On quarter basis. XX.X X.X last $X.XX $X.XX XXX,XXX or compared per GAAP on X.X $X.XX per million

increase of million, XX% just of XXXX for EBITDA versus was first million year the million the quarter. an X.X prior or under in Our XX.X quarter XX.X

related like accounting provision tax quarter change a of being to effective to under X.X new the reported Just looks first rate pronouncements. in that XX%. ASU the accounting are includes point out The tax million wanted charge

with you be this consistent expect charge were previous to run rate tax we If exclude our effective rates. our to

balance sheet, the equivalents September million. investments cash of totaled short-term XX, and cash as XX and XXXX Turning to

million was our million XXX share. $XX.XX capital Our shareholder equity working per or and XXX was

senior XXX.X bank approximately million including was total our under debt and XXX Our credit million facility. convertible

debt net was senior Our ratio X.XX secured times. leverage

June As Bill mentioned XX.X decreased year-end at versus XXX.X receivables for XX, trade million XXX.X by our earlier million million quarter-end our XXXX. to fiscal

we was Collections from days and -- consolidated continued we XX% that at at As have particularly XX products trade me, strong select XX the the $X.XX, past our to customers two quarter. XXXX. down days June result days lack from Rising at DSOs X/XX company's X/XX/XXXX. Rising as from versus over total AR X/XX/XXXX to XX, on approximately of were the benefit net came June August trading were down reductions discussed a price trade days receivables. in pardon Rising's [ph] XXX July as at net XX XX, of the DSOs

However, Rising XX run sub level have a day while at went is likely DSOs we're XX pleased not this few coming not likely few we things to this the way in know sustainable quarters. our and is sub a quarter rate

in fiscal we have this a resulted and June as the disclosed sales year-ended income and filed XXXX. recorded and $X of reduction that correction net million XX, related X-K XXXX we trade receivables the cash decrease XXXX. of morning to we The Finally, identified XX, in of an which an of X.X million June misapplication a adjustment of for in

this is XXXX determined are our We adjustment financial fiscal not material statement. to

XXXX The We the will our to go XX, -- to for ended September amendment XX-K(a) company report to monitor pardon causes its fiscal We amendment, the XXXX. we remediated ended of basis. matter. this of that as we XX-K(a) will upcoming annual XX, the file believe for June for June material the and will reflect on Form to underlying in to ensure year-ended XXXX effectiveness remediation this to have the reflect me, test expect Form XX-Q a year continue on fully describe it quarter more forward our this weakness the an

call operator to back the over turn to like would I questions. Now for the

Operator

Instructions]. [Operator

The Please Steadman go with ahead. comes question first from Dewey Canaccord.

Dewey Steadman

a you've while cycle the customer cycles other well out factors? question Good been new is generics welcome obviously more just morning is the on first on this and shaking as quite and the industry and role in My cycles of prolonged than and because to be generic several around consolidation the on is the external you've congratulations cycle. for previous to or Walt seen jungle. and Bill, the severe Bill

William C. Kennally

talking Nice the with you. for question Thanks Dewey.

here, is point all be is keys, a of think cycle. first onto it a it I might you two

while remember the marketplace, for of little downturn into who was around there significant now. what pricing us can came similar lasted Indian the a companies and think have for to to environment we're the when seeing I back first been really that those a

few consolidation. less think And of were versus were were now competitors from I then difference customers -- there were is generic there there one is more being that less the the and FDA. a approved

on particular So say were think especially that a I scale we're painful market I will in this not with if turn the seeing and is we to but what been inconsistent recovery. see a

Dewey Steadman

I announced market [indiscernible] and [ph] that a guess going factored on are a from what reduction in to on guidance? Great, Sigma thoughts product, has and into gross competing that the to launch launch competitive they're impact and your was the there margin the revenue potential

William C. Kennally

hi [ph] absolutely you're approval did Dewey, take the Sigma one product. right. an yeah, I'll that and get on Yeah

of We and seeing refreshing to some one of absolutely contributing remainder and it XXXX our the activity the has is are our in that factors marketplace into model. for been the fiscal factored thinking

Dewey Steadman

lumpy to want details don't Excellent, there? there obviously they you're not XXXX are I important, but are any don't even in to for and going there any particularly are are know launches that -- you don't we give we but out or what reasons competitive

William C. Kennally

When lumpy Dewey. you mean do mean you what

Dewey Steadman

XX? Sort those others out more particularly upcoming that that important to XX of are any of launches are than

William C. Kennally

to a of so You are run the triples know, don't timely basis. I But to home important think to all launch all, products first on speak. our be that ensure are any we going I for think of that us

Dewey Steadman

our companies that Okay, ERP XQ should to I of modeling and aspects that -- terms implementation we stopped the many in is in concern conversion, any or then versus an want question, modeling shipping concerns conversion? ERP any pharma make related not there of ahead ERP XQ models but

William C. Kennally

be thanks of there period for inventory with the in be it implementation. the it which that would as in -- build So, part weeks see. prior but could the customers year. to depends extra channel historically towards on something more you're of you reflected make see to of just probably than the of third was the aware inventory might going live quarter you I Dewey a if that that that would I'd couple -- might end but the of think the this the expect on customer and Historically be is surprised an

Dewey Steadman

what's final you for and first to my And not weeks working experience? of in question think Okay. working in Bill your the do role sort prior is broadly, is relative your what Aceto

William C. Kennally

world. I the The that gave some one example us giving show think in XX a really will really the China example say interesting is of if the you that take been is I the just SWAT with have I to if model the analysis from of asset have favorable for exciting. and it a clearly organization great The like Well, around order strength last being done we work -- I that's days and lot in people think results from standpoint a you like company. flexibility our would partners

what here's to like that get they can partners We not the us see where I'm to I'd of are model. One our yet for to what which can partners partners things and is I'd for you. me. to do in partners we go and go to I the ask that do, you say sorry, you to go sure the what do to and we say here's like the need

So that's as say would evolving necessarily but that that I well. I say to a we're weakness wouldn't

XX full my will go leaders that and company's prepared people challenges leaders, and with strategies last overall that's meeting below goal can visit mentioned that partners been in here we implement go to a doing with necessary goal of the the company be to kind addressing is of I from with are days, competitive. be over meeting plan those and out I as to customers From work on can. so the understand best and the the business the with I've circle what think essentially what comments inside our to the I my So, to

Dewey Steadman

Great, thank the for you questions. very much

Operator

question The comes next with Craig-Hallum from Matt Hewitt ahead. Capital go Please Group.

Matthew Hewitt

Good the new gentlemen, on Bill morning congratulations role.

William C. Kennally

Nice talk to with you. Matt. you Thank

Matthew Hewitt

the resolved, will been over longer-term years, in regarding driving API more out API not that resolved? as do A and any you those on helpful? will first facilities, you these look it issues you what's if I'm think displacements, next API quarter, is I those it issues the color it faced side, is on questions, get the international few to those been quarters the or have of And be the guess take couple scrutiny some how of long FDA curious

William C. Kennally

be So to the I I year. corrected ask fiscal think that shortfall that's add to the of is the the API might point now going anticipate we Walt but of by end

issues address some related have the that. So had specifics can maybe to that on Walt we technical and

Walter Kaczmarek

Right, hi Matt.

share issues of goal. So of being and other one a to as end is products so the corrected fully to have issue two an where we combination as Bill the a mentioned the in fully in as of share particular issue we API different And completely much have get what able anticipate we those of market impacted, our the it's more constraint both the year. fiscal fulfill to not need technical market we're those of is that couple API factors of by

Matthew Hewitt

performance you could excuse an I'm low fruit longer thank changes wondering things see the bigger over or those hanging a through changes, up moving you. realize you. quickly on for it's you're example, little of maybe you've new possible, the any you color as division, any as the me, been Thank could bit as low there that's one come that are you there the be you if has Bill as would couple years past come I chemicals helpful? that of get implement there's and look organization return any then look larger as out on hanging fruit, and Okay board and changes, immediate any

William C. Kennally

Sure for Matt, question. the thanks

some think one customer the I will As kind of business I opportunities in what especially the the there and take that organization light that are we the in forecast look base. look short-term not around is opportunities consolidation revision our at a considering of we're looking closely the themselves present things at of especially of

work the that. that's some looking there's exactly scenes So on behind at going

to generate additional what there. we our is that at do looking we share the right example, shares out For have business it do market market can there,

So what board have depicted as able I business comments the chain focus business. in one up we partners one I be do I hope white right like you product I back opportunity that I that slide think on. that side that model not my and in challenges at that area that's boxes. have In of in longer-term control move the up, though we we're is asset in higher if some with in on our with to have we think where generic going portfolio product the think that's mentioned the as the to opportunities are of value is we're a some to our have But of we we great now we our of the even prepared look

our if in maybe would might in-house could nice it R&D, be road. taking mean at more be a a really house business we manufacturing control So that down in of and having look the

the can Rising in two the as with opportunities looking try well, quarter for we've and other obviously So this across maintain only with in create this the some chemicals the to other performance the tough momentum value business seen businesses that but not we businesses as well. short-term environment with

Matthew Hewitt

Great, and Thank just last from queue, impact was in last quarters? will the one back the or that an QX you. two whack I hop done the One me, changes thank were in most recent cuts from then in any there you. or quarter

Douglas Roth

every Yes, Matt benefits and low a hanging reaped and few ago I the question. and more look look There the occurred each changes month fruit whack we we quarter. price molecule impactful quarter. the virtually field months and at will this the at that we There whack every

not During dials. there but opportunistic not were a just any they not and quarter -- likely move there were were this few

William C. Kennally

could to performs said to be a declines see manage we if and I have we're of that is Doug Matt, a Yet whack as this add the ASP that Rising going routine continued ongoing to spread. cadence to our net going closely to part as

will DSO that order have and a even to process. an so ongoing on continue to line whacks across going continue we're ongoing cadence in those to be to modify in it manage to So an it keep straight

Matthew Hewitt

Understood, thank alright, you.

William C. Kennally

Thanks Matt.

Operator

question with The Please ahead. Steve comes next Analysis. Schwartz First go from

Steve Schwartz

and everybody Bill. morning welcome Good

about looks it it up were looking First for to your now the the behind like like you of you to year, you couple down us if different on thing guidance reduced a last as R&D XX. report, things looks spend bottom the might you could what's of of connect talked clear Bill the be that that there? end of million for XX a spending, range it's at but make happening

William C. Kennally

and the Steve. what and a based -- we quarter. as lowered the you we milestone the is of Thank in know for spend have R&D the it sure Yes, guidance you think Look the budget have at on we've based is lower question. our I end just put the first

then So a to if additional due some up look we flex at opportunities we'll to need take that.

Steve Schwartz

opportunities in to opportunities a that puts occurred parked give terms sense or but and longer nearer-term different you the the commercial like years, can commercial those products that by were you within and pipeline, farther the is related that us out takes number have of Okay, lower there?

Walter Kaczmarek

to These undergoing so near-term they're the being that an -- for of hi of filed ANDA. opportunities, so the not technical they're are Yeah, are process speak, products process Steve. in development

still off particular they're ways on months projects. to depending XX their So from XX a anywhere

is that So scenario. the

Steve Schwartz

all Okay, is this regions across all on segments, and business correct? transition, so three companywide ERP or it's is that groups the

Walter Kaczmarek

This for No, the is that's correct. not business. strictly Rising

segments two business other The separate system. a ERP have

Steve Schwartz

in several generally on just for was quarter and has that the what's driver, past Okay, France there strong first with in and results and and been Europe the then you driver been a too the what's has more I popped quarters, pharmaceutical you happening as just again respect ingredients, can case Germany up favorable? particularly that think going remind actually over us to has Singapore of

William C. Kennally

drivers lift now So, have out have some say to and portfolio is the to we're do revenue. goods so finished that FX getting starting Singapore of positive starting that we as we'll a a is there hold And one to drive concerned just is take far as the that. of

well. initiatives bear that We've put start Europe of see into of a grow resources bear that to happy hoping that starting continue are that other of world also going to business. particular to the we're lot in finished we're on and very effort, to fruit time, So part doses strategic fruit. got parts as to We're going and to to continue

paying Europe it's we're performing to bit little and So more a very attention well.

we're to that. happy So see

Steve Schwartz

good, me. that's it Okay, Thanks for very for taking the questions.

William C. Kennally

Steve. Thanks

Operator

Eisen Research. The ahead. comes Singular next question Greg Please with go from

Greg Eisen

welcome Aceto Thanks, and good Bill management. morning to

improving what health you has was segment gross forward? I be levers see improve and in the to margin margin the on think work the you company disposal wanting wondering its in prepared talked that would human I at going remarks about the the to

William C. Kennally

Well thanks Greg, I appreciate the question.

and partners that we there we in I that is going in are is profit. terms we to I business in and I the we work of at way the that try comments enjoy closely some to to activity But about say short-term the think that think I traditional some out think at with two would how can the gross a on working need relative it deliver at the really opportunities been that is area longer-term relationship. look higher the probably one look that made it's haven't box model explored of to in there can parts,

a to the is Our competitors. driver profit compared lower gross our for asset of as like some model primary

really what on front. comes on we front looking inside to and/or control the the to capabilities gross at profit our the it is that the perhaps So, manufacturing it having R&D and can even bringing increase when perhaps company more to business on over our relates do then that

these will and against improve If those too. help our can do situation. things we us execute it So those will us help

Greg Eisen

inside question Thanks company? surprised most? to for you had part, arrived since have the as stating on the that job CEO so my What you One biggest surprise been seen more the clearly. you've what's that you've

William C. Kennally

Greg. tongue a you You on of I've experience that a lot. I candidly leadership tied a tell surprised can little that had mean one I been probably had haven't by I lot historically. me

general problems people in can. hinting think that area. I the of to haven't trying are that job any seen they I do best in

I've days. experience in kind my everything think really as just the I prepared leader about of me a just first everything, for experienced has that XX about

Greg Eisen

thanks well question. that Great, answering for

William C. Kennally

Greg. Yes that on sure, you tied got me little tongue a

Greg Eisen

It's okay, thanks.

Operator

go Main with McKenna Kevin from comes question Line Please ahead. Capital. next The

Kevin McKenna

Good just my is question morning, you side thank you really say that -- more Mr. morning, trying is to good Kennally everyone. my over What do get of a to the request. get would trying to to I'm of I I'm table.

say value with actually the division by cap, minus chemical company about just the of a $XXX right that's near plus the at now million a looking or or would You're people itself. market some value

do near selling own the in stock that option I And think by maybe filed eat ownership What not see XX am granted. should cooking, for that want the Egger that I selling? $XX that exercising at from like work the or in at to not Aceto see a all if Aceto would so to stock I months, gone has had granted would on to buying should reward are institute these people I about culture like I'd be their is you management we at results look levels for to to getting the that under I'd $XX with see is like you been paid say X that Search this guys options Form a but you management. and

William C. Kennally

I appreciate your look for and to want thank Kevin, I Well you the comment suggestion.

Kevin McKenna

what I that's got. Well,

William C. Kennally

Thank very you much.

Operator

The next investor. comes Patrisie ahead. question private go Please from Lester a [ph]

Unidentified Analyst

in, something Good maybe looks I the shares, X.X is and going a morning yet including has confused share is thought It the a serial come you the in simply but those first you're deal suggest it is true that crack quarter else second for what about the like I'm amounts true is step outstanding. maybe equal million the were over there quarter the two quarter questions now Doug? it into And quarter, at Roth like would EBITDA takes up was looks thing fellows, increased? or just to the I the that fourth accelerated quarterly Citron is next Douglas consideration. still count this

Douglas Roth

X million were -- And of the technically but need from they for our shares diluted issued the them and count. the outstanding I we yet That the answer to don't The share the included we is in Well me basic XX.X issued include shares quarter first let terms versus purposes -- Lester for to that million weren’t million. question the XX.X EBITDA seller. accounting was have do last transaction. consistent first. in in of the year

Unidentified Analyst

of going too shouldn't we isn’t change. amount? I a much the Okay, see dilution mean full your forward so

Douglas Roth

million in XX The Lester. Correct should change future. the hope for that

Unidentified Analyst

this ambitious your heard aggressive few it's be imperatives And days box. and in early most I from goal going liked know heard there executive I what make on in investor experience for can years, well, thank your chemical would so you or for, some a very you your would important former appreciated organization your and and where a that of your but an go M&A to words patience taker we strategic be $X leadership industries overnight. expect is is with XXXX, really a CEO you're large articulated have have welcome of just laid in you and I've well. going take narrative, all Stanley hear if a billion are some certain has I'm I aren’t driven, that know is I or we want amount what years concept heavy demonstrated lacking pots Morgan a touched something it's going down and organization, in to that company of manufacturing to that words pans how with it changes we us, years, conference was that a away And from the and produce And and a to veteran was narrative I something to wrote investing are I risk you is do XXXX you a to the like investor. make I what aboard crisp from to with suggestion years you're especially I and going would investor and I taken comment, calls. in pharmaceutical oriented the $X the as to I what but to sixty think and in haven't But APIs, often forward. strategic company a us? my Conference you me add margin something think what may three plan to a I we're it strategic William. talk narrative in at quarters XX success should you're I to think narrative the we been would in a are going take be the but understand prior certainly chemistry billion as what in articulate and appreciate ours, strength touched get at I mentioned least for place you an strategic I and to required criticism improvement CAPEX You've spadework am on in and five segue vision sorry, and hearing been calls rather, don't the expect also sixty conference refreshed manufacturing, the and that's invest you these me past of not for put

drug expertise, strategy, or drug the and this and finished dress. to to product giving are us away perhaps explore formulation merit or through dosage help who partners packaging our form is model discovery a both capture even would the providing or leaves tech further homegrown integration XX% that there acquiring we're the that So in delivery acquisition our to to finished technology dosage forward either the

to in participants aboard meantime crisp would could the us. articulation, the our you on But welcome and new bookends, I expect appreciate the future all in think take if call captain. I this appreciate So a where would you more

William C. Kennally

Lester very to don't me much William. wife appreciated your comments as to me. My she's and at much for Bill Well, be not you from I by calls time angry at William me you way thank I'm so time the angry when want

of one a possibly your where have to you going to line if things then do with adding Because to implement I think taking but plan is in want some a it you our you get and ripping I plan up to So comments might it look don't expectations go. be. what not at soon not necessarily look great made strategic and the plan you're

think my whiteboard paper, comments intermediate of need discuss the pen what are that bring you're made exactly that and the for we long-term, And and that's is So strategies I out do opportunity there. of company asking the to we then to many to you part implement. to the put and that planned is what in

comments very appreciate much. So them advisement your I I take under and

Unidentified Analyst

a beautiful the of beginning somewhat… So this relationship, could be

William C. Kennally

certainly And thank the your Well, I so. of for you support much company. hope very

Unidentified Analyst

Bill. Good you to luck

William C. Kennally

you. Thank

Operator

back our Bill like remarks. closing I concludes would session. Kennally for to turn question-and-answer over to conference any the This

William C. Kennally

you conference by to a was appreciate the I call to great fiscal operations on quarter XXXX up. call you conference intend good for a how my day all and to you. us forward XXXX coming clarity company it. and what our in everyone Nice See and February Anita, and going on for quarterly I second pleasure first was Thanks I I today. later. hope the I weekend provide everyone regarding joining manage a in call. today to has speaking you certainly you again And with in And It with you forward. meeting participating able I job can I look some thank to wanted our of bring hope

Operator

for attending presentation. concluded. now is conference you Thank today's This

You may now disconnect.